Animal Model | Liposome Formulation | Dose6-a | Plasma | Tumor | Spleen | Liver | Heart | Lung | Kidney |
---|---|---|---|---|---|---|---|---|---|
mg/kg | μg · h/ml | μg · h/g | |||||||
BALB/c mice with C26 colon carcinoma6-b 6-d | DSPC/Chol/GM1(2:1:0.2) | 6-c | 662.2 | 1974 | 1299 | 83.25 | 141.5 | 241.8 | |
DSPC/Chol (2:1) | 6-c | 256.2 | 3348 | 1757 | 31.98 | 28.3 | 40.48 | ||
Female BDF1 mice6-e | DSPC/Chol (55:45) | 10 | 1095.2 | 470.6 | 8923.8 | 2444.5 | 67 | 1265.6 | |
Free DOX | 7.5 | 1.3 | 73.8 | 496.9 | 874.9 | 820.4 | 1258.1 | ||
BALB/c mice with colon C26 carcinoma6-f | PEG-PE/DSPC/Chol (6:47:47) | 5 | 809.5 | 169.6 | 320.3 | 309.4 | 41.9 | 91.4 | 132.0 |
DSPC/Chol (1:1) | 5 | 342.8 | 50.1 | 365.5 | 341.4 | 41.2 | 67.5 | 72.4 | |
Free DOX | 5 | 1 | 18.1 | 178.1 | 168.8 | 63.2 | 106.4 | 146.1 | |
BALB/c mice with P1798 lymphosarcoma6-g | DSPC/Chol (2:1) (62 nm) | 20 | 2275.6 | 2470.5 | 3596.2 | 693.6 | 265.1 | 685.0 | 1237.2 |
Free daunorubicin | 20 | 10 | 245.1 | 2213.4 | 335.5 | 249.9 | 612.2 | 976.8 | |
BDF1 mice6-h(mitoxantrone) | DSPC/Chol | 10 | 1970 | 12630 | 4832 | 178 | 751 | ||
DSPC/Chol/PEG-PE | 10 | 4863 | 7242 | 4302 | 218 | 697 |
AUC was calculated from either 0–96 h,d 1–24 h,f by the trapezoidal rule,e, h or 0–48 h.g
↵6-a Dose is given in mg/kg DOX.
↵6-b Data were collected using encapsulated 67Ga as the tracer. The tissue distribution is expressed as percent of injected dose per gram of tissue versus time (h).
↵6-c 10–15 μmol of phospholipid/kg.
↵6-d Huang et al. (1992). Data were collected using encapsulated67Ga as the tracer. The tissue distribution is expressed as percent of injected dose per gram of tissue versus time (h) after injection.
↵6-e Krishna and Mayer (1997).
↵6-f Unezaki et al. (1995).
↵6-g Forssen et al. (1992).
↵6-h Chang et al. (1997).